Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Lasers in Medical Science
Published in: Lasers in Medical Science 3/2004

01-12-2004 | Original Article

Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy

Authors: Asta Juzeniene, Petras Juzenas, Li-Wei Ma, Vladimir Iani, Johan Moan

Published in: Lasers in Medical Science | Issue 3/2004

Login to get access

Abstract

Many medical applications, including photodynamic therapy for cancer (PDT), involve the use of lasers. However, the coherence of laser light is not necessary for PDT, and attempts have been made to construct non-coherent light sources for PDT, which are relatively inexpensive, stable and easy to operate, require simple maintenance but differ fundamentally from the lasers in their output characteristics. In the present work we compared two clinically used lamps, CureLight1, which is a broadband source (560–740 nm) based on a filtered halogen lamp, and CureLight2, which is a narrowband source based on light-emitting diodes (LEDs), with respect to several parameters of crucial significance for PDT efficiency in vivo: (a) depth of action in tissues, (b) heating effects, (c) pain generation, (d) photodegradation of PpIX in solution, in cells and in mouse skin and (e) photo-inactivation of cells in vitro. We conclude that CureLight2 (LED), relative to CureLight1 (halogen) has deeper PDT action in tissue, similar efficiency for bleaching PpIX in mouse skin, better efficiency for bleaching PpIX in cells and solutions and good efficiency for inactivating cells in vitro. CureLight2 gives less heating of the tissue and less pain in unsensitised human skin. All these differences are related to difference in the spectra of the lamps. Thus, PDT light sources with emissions that are visually similar have significantly different photobiological properties.
Literature
1.
Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90:889–905CrossRefPubMed
2.
Kalka K, Merk H, Mukhtar H (2000) Photodynamic therapy in dermatology. J Am Acad Dermatol 42:389–413CrossRefPubMed
3.
4.
Zeitouni NC, Shieh S, Oseroff AR (2001) Laser and photodynamic therapy in the management of cutaneous malignancies. Clin Dermatol 19:329–338
5.
Azizkhan RG (2003) Laser surgery: new applications for pediatric skin and airway lesions. Curr Opin Pediatr 15:243–247CrossRefPubMed
6.
Al Buainian H, Verhaeghe E, Dierckxsens L, Naeyaert JM (2003) Early treatment of hemangiomas with lasers. A review. Dermatology 206:370–373CrossRefPubMed
7.
Papadavid E, Katsambas A (2003) Lasers for facial rejuvenation: a review. Int J Dermatol 42:480–487CrossRefPubMed
8.
9.
Szeimies RM, Hein R, Baumler W, Heine A, Landthaler M (1994) A possible new incoherent lamp for photodynamic treatment of superficial skin lesions. Acta Derm Venereol 74:117–119PubMed
10.
Brancaleon L, Moseley H (2002) Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci 17:173–186CrossRefPubMed
11.
Whitehurst C, Byrne K, Moore JV (1993) Development of an alternative light source to lasers for photodynamic therapy: 1. Comparative in vitro dose response characteristics. Lasers Med Sci 8:259–267
12.
Whitehurst C, Humphries JD, Moore JV (1995) Development of an alternative light source to lasers for photodynamic therapy: 2. Comparative in vivo tumour response characteristics. Lasers Med Sci 10:121–126
13.
Morton CA, Whitehurst C, Moseley H, Moore JV, MacKie RM (1995) Development of an alternative light source to lasers for photodynamic therapy: 3. Clinical evaluation in the treatment of pre-malignant non-melanoma skin cancer. Lasers Med Sci 10:165–171
14.
Moseley H (1996) Total effective fluence: a useful concept in photodynamic therapy. Lasers Med Sci 11:139–143
15.
Soler AM, Angell-Petersen E, Warloe T, Tausjo J, Steen HB, Moan J, Giercksky KE (2000) Photodynamic therapy of superficial basal cell carcinoma with 5- aminolevulinic acid with dimethylsulfoxide and ethylenediaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 71:724–729CrossRefPubMed
16.
Clark C, Bryden A, Dawe R, Moseley H, Ferguson J, Ibbotson SH (2003) Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed 19:134–141PubMed
17.
Moan J, Peng Q, Evensen JF, Berg K, Western A, Rimington C (1987) Photosensitizing efficiencies, tumor- and cellular uptake of different photosensitizing drugs relevant for photodynamic therapy of cancer. Photochem Photobiol 46:713–721PubMed
18.
Georgakoudi I, Nichols MG, Foster TH (1997) The mechanism of photofrin photobleaching and its consequences for photodynamic dosimetry. Photochem Photobiol 65:135–144PubMed
19.
Mang TS, Dougherty TJ, Potter WR, Boyle DG, Somer S, Moan J (1987) Photobleaching of porphyrins used in photodynamic therapy and implications for therapy. Photochem Photobiol 45:501–506PubMed
20.
Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star WM (1999) Protoporphyrin IX fluorescence photobleaching during ALA-mediated photodynamic therapy of UVB-induced tumors in hairless mouse skin. Photochem Photobiol 69:61–70CrossRefPubMed
21.
Rotomskis R, Bagdonas S, Streckyte G, Wendenburg R, Dietel W, Didziapetriene J, Ibelhauptaite A, Staciokiene L (1998) Phototransformation of sensitizers: 3. Implications for clinical dosimetry. Lasers Med Sci 13:271–278
22.
Svaasand LO, Wyss P, Wyss MT, Tadir Y, Tromberg BJ, Berns MW (1996) Dosimetry model for photodynamic therapy with topically administered photosensitizers. Lasers Surg Med 18:139–149CrossRefPubMed
23.
Wilson BC, Patterson MS, Lilge L (1997) Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. Lasers Med Sci 12:182–199
24.
Longnecker DE, Harris PD (1980) Microcirculatory actions of general anesthetics. Fed Proc 39:1580–1583PubMed
25.
Juzeniene A, Juzenas P, Kaalhus O, Iani V, Moan J (2002) Temperature effect on accumulation of protoporphyrin IX after topical application of 5-aminolevulinic acid and its methylester and hexylester derivatives in normal mouse skin. Photochem Photobiol 76:452–456CrossRefPubMed
26.
Jensen EW, Nygaard M, Henneberg SW (1998) On-line analysis of middle latency auditory evoked potentials (MLAEP) for monitoring depth of anaesthesia in laboratory rats. Med Eng Phys 20:722–728CrossRefPubMed
27.
Noguchi P, Wallace R, Johnson J, Earley EM, O’Brien S, Ferrone S, Pellegrino MA, Milstien J, Needy C, Browne W, Petricciani J (1979) Characterization of the WIDR: a human colon carcinoma cell line. In Vitro 15:401–408PubMed
28.
Juzeniene A, Ma LW, Juzenas P, Iani V, Lange N, Moan J (2002) Production of protoporphyrin IX from 5-aminolevulinic acid and two of its esters in cells in vitro and tissues in vivo. Cell Mol Biol 48:911–916
29.
Juzeniene A, Juzenas P, Iani V, Moan J (2002) Topical application of 5-aminolevulinic acid and its methylester, hexylester and octylester derivatives: considerations for dosimetry in mouse skin model. Photochem Photobiol 76:329–334CrossRefPubMed
30.
Moan J, Peng Q, Sorensen R, Iani V, Nesland JM (1998) The biophysical foundations of photodynamic therapy. Endoscopy 30:387–391PubMed
31.
Juzenas P, Juzeniene A, Kaalhus O, Iani V, Moan J (2002) Noninvasive fluorescence excitation spectroscopy during application of 5-aminolevulinic acid in vivo. Photochem Photobiol Sci 1:745–748CrossRefPubMed
32.
Moan J, Kessel D (1988) Photoproducts formed from photofrin II in cells. J Photochem Photobiol B 1:429–436CrossRefPubMed
33.
Svaasand LO (1985) Photodynamic and photohyperthermic response of malignant tumors. Med Phys 12:455–461CrossRefPubMed
34.
Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM (1997) 5-aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 79:2282–2308CrossRefPubMed
35.
Robinson DJ, de Bruijn HS, de Wolf WJ, Sterenborg HJ, Star WM (2000) Topical 5-aminolevulinic acid-photodynamic therapy of hairless mouse skin using two-fold illumination schemes: PpIX fluorescence kinetics, photobleaching and biological effect. Photochem Photobiol 72:794–802CrossRefPubMed
36.
Moan J (1984) The photochemical yield of singlet oxygen from porphyrins in different states of aggregation. Photochem Photobiol 39:445–449
37.
Reddi E, Jori G (1988) Steady state and time-resolved spectroscopic studies of photodynamic sensitizers; porphyrins and phthalocyanines. Rev Chem Intermed 10:241–268
38.
Negri RM, Zalts A, San Roman EA, Aramendia PF, Braslavsky SE (1991) Carboxylated zinc-phthalocyanine, influence of dimerization on the spectroscopic properties. An absorption, emission and thermal lensing study. Photochem Photobiol 53:317–322
39.
Juzenas P, Sharfaei S, Moan J, Bissonnette R (2002) Protoporphyrin IX fluorescence kinetics in UV-induced tumours and normal skin of hairless mice after topical application of 5-aminolevulinic acid methyl ester. J Photochem Photobiol B 67:11–17CrossRefPubMed
40.
Juzenas P, Iani V, Bagdonas S, Rotomskis R, Moan J (2001) Fluorescence spectroscopy of normal mouse skin exposed to 5-aminolaevulinic acid and red light. J Photochem Photobiol B 61:78–86CrossRefPubMed
41.
Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star WM (1998) Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem Photobiol 67:140–149
42.
Finlay JC, Conover DL, Hull EL, Foster TH (2001) Porphyrin bleaching and PDT-induced spectral changes are irradiance dependent in ALA-sensitized normal rat skin in vivo. Photochem Photobiol 73:54–63CrossRefPubMed
43.
Moan J, Juzenas P, Bagdonas S (2000) Degradation and transformation of photosensitizers during light exposure. In: Pandalai SG (ed) Recent Research Developments in Photochemistry and Photobiology, Transworld Research Network Trivandrum, pp 121–132
44.
Konig K, Felsmann A, Dietel W, Boschmann M (1990) Photodynamic activity of HpD-photoproducts. Studia Biophys 138:219–228
45.
Giniunas L, Rotomskis R, Smilgevicius V, Piskarskas AP, Didziapietriene J, Bloznelyte L, Griciute L (1991) Activity of haematoporphyrin derivative photoproduct in photodynamic therapy in vivo. Lasers Med Sci 6:425–428
46.
Konig K, Schneckenburger H, Ruck A, Steiner R (1993) In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins. J Photochem Photobiol B 18:287–290CrossRefPubMed
47.
Wessels JM, Sroka R, Heil P, Seidlitz HK (1993) Photodegradation of protoporphyrin-dimethylester in solution and in organized environments. Int J Radiat Biol 64:475–484PubMed
48.
Ma L, Bagdonas S, Moan J (2001) The photosensitizing effect of the photoproduct of protoporphyrin IX. J Photochem Photobiol B 60:108–113CrossRefPubMed
49.
Bonnett R, Martinez G (2001) Photobleaching of sensitisers used in photodynamic therapy. Tetrahedron 57:9513–9547CrossRef
50.
Bagdonas S, Ma LW, Iani V, Rotomskis R, Juzenas P, Moan J (2000) Phototransformations of 5-aminolevulinic acid-induced protoporphyrin IX in vitro: a spectroscopic study. Photochem Photobiol 72:186–192CrossRefPubMed
51.
Moan J (1986) Effect of bleaching of porphyrin sensitizers during photodynamic therapy. Cancer Lett 33:45–53CrossRefPubMed
52.
Brun A, Western A, Malik Z, Sandberg S (1990) Erythropoietic protoporphyria: photodynamic transfer of protoporphyrin from intact erythrocytes to other cells. Photochem Photobiol 51:573–577PubMed
53.
Moan J, Streckyte G, Bagdonas S, Bech O, Berg K (1997) Photobleaching of protoporphyrin IX in cells incubated with 5-aminolevulinic acid. Int J Cancer 70:90–97CrossRefPubMed
54.
Krieg M, Whitten DG (1984) Self-sensitized photo-oxidation of protoporphyrin iX and related porphyrins in erythrocyte ghosts and microemulsions: a novel photo-oxidation pathway involving singlet oxygen. J Photochem 25:235–252CrossRef
55.
Stender IM, Na R, Fogh H, Gluud C, Wulf HC (2000) Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 355:963–966CrossRefPubMed
56.
Lui H, Anderson RR (1993) Photodynamic therapy in dermatology: recent developments. Dermatol Clin 11:1–13CrossRefPubMed
57.
Grapengiesser S, Ericson M, Gudmundsson F, Larko O, Rosen A, Wennberg AM (2002) Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 27:493–497CrossRefPubMed
58.
Fijan S, Honigsmann H, Ortel B (1995) Photodynamic therapy of epithelial skin tumours using δ-aminolaevulinic acid and desferrioxamine. Br J Dermatol 133:282–288PubMed
59.
Fuchs J, Thiele J (2003) The role of oxygen in cutaneous photodynamic therapy. Free Radic Biol Med 24:835–847CrossRef
60.
Warloe T, Peng Q, Moan J, Qvist HL, Giercksky KE (1992) Photochemotherapy of multiple basal cell carcinoma with endogenous porphyrins induced by topical application of 5-aminolevulinic acid. In: Spinelli P, Dal Fante M, Marchesini R (eds) Photodynamic therapy and biomedical lasers. Elsevier, Milan, pp 449–453
61.
Fritsch C, Stege H, Saalmann G, Goerz G, Ruzicka T, Krutmann J (1997) Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses. Photodermatol Photoimmunol Photomed 13:181–185PubMed
62.
Morton CA, Whitehurst C, Moore JV, MacKie RM (2000) Comparison of red and green light in the treatment of Bowen’s disease by photodynamic therapy. Br J Dermatol 143:767–772CrossRefPubMed
63.
Stringer MR (1995) Problems associated with the use of broad-band illumination sources for photodynamic therapy. Phys Med Biol 40:1733–1735CrossRefPubMed
64.
Roberts F (1996) Comments on ‘Problems associated with the use of broad-band illumination sources for photodynamic therapy’. Phys Med Biol 41:1517–1518CrossRefPubMed
65.
Kelleher DK, Thews O, Scherz A, Salomon Y, Vaupel P (2003) Combined hyperthermia and chlorophyll-based photodynamic therapy: tumour growth and metabolic microenvironment. Br J Cancer 89:2333–2339CrossRefPubMed
66.
Metadata
Title
Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy
Authors
Asta Juzeniene
Petras Juzenas
Li-Wei Ma
Vladimir Iani
Johan Moan
Publication date
01-12-2004
Publisher
Springer-Verlag
Published in
Lasers in Medical Science / Issue 3/2004
Print ISSN: 0268-8921
Electronic ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-004-0314-x

Other articles of this Issue 3/2004

Lasers in Medical Science 3/2004 Go to the issue

Original Article

Photohemolysis of erythrocytes by He-Ne laser irradiation: the effect of power density

Letter to the Editor

The combination of optical and electrical energies produces different histological findings from when laser alone is used in leg vein treatment

Original Article

Tissue ablation-rate measurements with a long-pulsed, fibre-deliverable 308 nm excimer laser

Original Article

Transmission of Q-switched erbium:YSGG (λ=2.79 μm) and erbium:YAG (λ=2.94 μm) laser radiation through germanium oxide and sapphire optical fibres at high pulse energies

Meeting Report

Abstracts - Laser Florence 2004

Original Article

Application of lower fluence rate for less microvasculature damage and greater cell-killing during photodynamic therapy